Abstract library

6 results for "Cwikla".
#163 Clinical value of MRI DWI and (Gd-EOB)-DTPA to assess liver involvement in patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Introduction: Standard MRI, including breath-hold techniques with SE T1 and T2 weighted images, biochemical shift, and 3D GRE and also T1 images after gadolinium enhancement Gd-DTPA, are useful in detecting liver lesions in patients with advanced GEP-NET. Recently, new algorithms of MRI, including diffusion-weighted imaging MRI (DWI) and i.v. (Gd-EOB)-DTPA (Primovist) contrast enhancement, seems to be promising in the detection of liver deposits.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Jaroslaw B Cwikla
#970 Progression-Free Survival (PFS) and Tumor Growth with Lanreotide Autogel (LAN) in Patients (Pts) with Enteropancreatic NETs: Results from CLARINET, a Randomized, Double-Blind, Placebo (Pbo)-Controlled Study
Introduction: Prospective data on antiproliferative effects of somatostatin analogs are lacking in grade 2 and non-midgut tumors.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Professor Martyn Caplin
Keywords: tumor response
#1185 Lanreotide Autogel (LAN) 120 mg in Patients with Progressive Enteropancreatic (EP-) NETs: Data from the CLARINET Open-Label Extension (OLE) Study
Introduction: In the CLARINET core study, LAN 120 mg significantly prolonged PFS vs placebo (PBO) in metastatic grade 1 or 2 EP-NETs.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Martyn Caplin
#1188 Antitumor Treatment with Lanreotide Autogel 120 mg (LAN) for Enteropancreatic (EP-)NET: Update from the CLARINET Open-Label Extension (OLE) Study
Introduction: In CLARINET, LAN had significant antitumour effects vs placebo (PBO) on metastatic G1/G2 EP-NETs, liver burden ≤ and >25%, and 96% SD prior to LAN.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Martyn Caplin
Authors: Caplin M, Pavel M, Cwikla J B, Phan A T, ...
#1193 Health-Related Quality of Life (HRQoL) with Lanreotide Autogel (LAN) 120 mg in Patients with Enteropancreatic (EP-) NETs: Post Hoc Analyses from the CLARINET Study
Introduction: In CLARINET, favourable efficacy and safety with LAN in metastatic EP-NETs was associated with stable HRQoL outcomes.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Martyn Caplin
Authors: Caplin M, Pavel M, Cwikla J B, Phan A T, ...
#1194 Chromogranin A (CgA) and PFS Outcomes in Lanreotide Autogel (LAN) in Patients with Metastatic Enteropancreatic (EP-) NETs: Data from the CLARINET Study
Introduction: The CLARINET study showed LAN 120 mg prolonged PFS vs. placebo (PBO) in patients with metastatic EP-NETs.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Martyn Caplin
Authors: Caplin M, Pavel M, Cwikla J B, Phan A T, ...
Keywords: lanreotide, biomarker